Faes Farma, S.A.

BME:FAE Stock Report

Market Cap: €1.1b

Faes Farma Past Earnings Performance

Past criteria checks 4/6

Faes Farma has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 5.4% per year. Faes Farma's return on equity is 14.2%, and it has net margins of 19.4%.

Key information

8.3%

Earnings growth rate

5.9%

EPS growth rate

Pharmaceuticals Industry Growth5.0%
Revenue growth rate5.4%
Return on equity14.2%
Net Margin19.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0332

Jan 06
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0332

Faes Farma's (BME:FAE) Dividend Will Be €0.0332

Dec 03
Faes Farma's (BME:FAE) Dividend Will Be €0.0332

Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Nov 03
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Dec 18
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Dec 04
Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Nov 24
Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

May 03
Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Sep 21
Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Is Faes Farma (BME:FAE) A Risky Investment?

Aug 03
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Jun 17
Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Is Faes Farma (BME:FAE) Using Too Much Debt?

Mar 27
Is Faes Farma (BME:FAE) Using Too Much Debt?

Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Dec 13
Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Nov 29
Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Is Faes Farma (BME:FAE) A Risky Investment?

Sep 21
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Is Faes Farma (BME:FAE) Using Too Much Debt?

May 01
Is Faes Farma (BME:FAE) Using Too Much Debt?

Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Apr 07
Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Mar 22
Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Mar 06
Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

Feb 22
Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Jan 16
I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Dec 08
Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Revenue & Expenses Breakdown

How Faes Farma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BME:FAE Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24504981310
30 Jun 24494971260
31 Mar 24482951230
31 Dec 23473921220
30 Sep 2347290980
30 Jun 23469901200
31 Mar 2346791960
31 Dec 22462891160
30 Sep 22460861130
30 Jun 2246688910
31 Mar 22449881110
31 Dec 2142982870
30 Sep 21416811070
30 Jun 21398741060
31 Mar 21394731040
31 Dec 20411731050
30 Sep 2040877920
30 Jun 20407731060
31 Mar 20409681060
31 Dec 19383641040
30 Sep 19379601140
30 Jun 1936359970
31 Mar 1935154950
31 Dec 1834052940
30 Sep 1833451870
30 Jun 1833049860
31 Mar 1830847810
31 Dec 1728241770
30 Sep 1726639700
30 Jun 1725039670
31 Mar 1724138660
31 Dec 1623737660
30 Sep 1622635640
30 Jun 1622234630
31 Mar 1622032620
31 Dec 1521430610
30 Sep 1520728591
30 Jun 1520327580
31 Mar 1519626450
31 Dec 1419825580
30 Sep 1419523601
30 Jun 1419424601
31 Mar 1419220601

Quality Earnings: FAE has high quality earnings.

Growing Profit Margin: FAE's current net profit margins (19.4%) are higher than last year (19%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: FAE's earnings have grown by 8.3% per year over the past 5 years.

Accelerating Growth: FAE's earnings growth over the past year (8.8%) exceeds its 5-year average (8.3% per year).

Earnings vs Industry: FAE earnings growth over the past year (8.8%) did not outperform the Pharmaceuticals industry 9.5%.

Return on Equity

High ROE: FAE's Return on Equity (14.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 21:35
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Faes Farma, S.A. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Álvaro Arístegui EchevarríaAhorro Corporación
Kamla SinghAlphaValue
Guilherme SampaioBanco BPI, S.A.